Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§)

por Horinouchi, Hidehito
Publicado 2016

To combine or not to combine: anti-vascular endothelial growth factor therapies in EGFR mutation positive non-small cell lung cancer

por Horinouchi, Hidehito
Publicado 2020

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance

por Araki, Taisuke, Kanda, Shintaro, Horinouchi, Hidehito, Ohe, Yuichiro
Publicado 2023

The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report

por Zang, Jing, Horinouchi, Hidehito, Hanaoka, Jun, Funai, Kazuhito, Sakakura, Noriaki, Liao, Hu
Publicado 2021

Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies

por Tanaka, Midori, Horinouchi, Hidehito, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Nokihara, Hiroshi, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2018

Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease

por Udagawa, Chihiro, Horinouchi, Hidehito, Shiraishi, Kouya, Kohno, Takashi, Okusaka, Takuji, Ueno, Hideki, Tamura, Kenji, Ohe, Yuichiro, Zembutsu, Hitoshi
Publicado 2019

Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer

por Kanda, Shintaro, Ohe, Yuichiro, Goto, Yasushi, Horinouchi, Hidehito, Fujiwara, Yutaka, Nokihara, Hiroshi, Yamamoto, Noboru, Yamamoto, Takanori, Tamura, Tomohide
Publicado 2020

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

por Takumida, Hiroshi, Horinouchi, Hidehito, Masuda, Ken, Shinno, Yuki, Okuma, Yusuke, Yoshida, Tatsuya, Goto, Yasushi, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2021

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer

por Tamura, Nobumasa, Horinouchi, Hidehito, Sekine, Katsutoshi, Matsumoto, Yuji, Murakami, Shuji, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2019

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody

por Murakami, Shuji, Shibaki, Ryota, Matsumoto, Yuji, Yoshida, Tatsuya, Goto, Yasushi, Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2020

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib

por Takeyasu, Yuki, Yoshida, Tatsuya, Masuda, Ken, Matsumoto, Yuji, Shinno, Yuki, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2022

Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world

por Kaku, Sawako, Horinouchi, Hidehito, Watanabe, Hirokazu, Yonemori, Kan, Okusaka, Takuji, Boku, Narikazu, Yamazaki, Naoya, Kawai, Akira, Ohe, Yuichiro, Kusumoto, Masahiko
Publicado 2022

Correction to: Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world

por Kaku, Sawako, Horinouchi, Hidehito, Watanabe, Hirokazu, Yonemori, Kan, Okusaka, Takuji, Boku, Narikazu, Yamazaki, Naoya, Kawai, Akira, Ohe, Yuichiro, Kusumoto, Masahiko
Publicado 2022

Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients

por Higashiyama, Ryoko Inaba, Horinouchi, Hidehito, Kuchiba, Aya, Matsumoto, Yuji, Murakami, Shuji, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2022

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer

por Makino, Yoshinori, Makihara‐Ando, Reiko, Ogawa, Takanori, Sato, Hitoshi, Goto, Yasushi, Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Ohe, Yuichiro, Yamamoto, Noboru
Publicado 2019

Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study

por Nakamura, Tomoaki, Yoshida, Tatsuya, Takeyasu, Yuki, Masuda, Ken, Sinno, Yuki, Matsumoto, Yuji, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2023

Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression

por Seki, Yoshitaka, Fujiwara, Yutaka, Kohno, Takashi, Yoshida, Kazushi, Goto, Yasushi, Horinouchi, Hidehito, Kanda, Shintaro, Nokihara, Hiroshi, Yamamoto, Noboru, Kuwano, Kazuyoshi, Ohe, Yuichiro
Publicado 2018

Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer

por Shibaki, Ryota, Murakami, Shuji, Shinno, Yuki, Matsumoto, Yuji, Goto, Yasushi, Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Motoi, Noriko, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2019

Mixed response to osimertinib and the beneficial effects of additional local therapy

por Shinno, Yuki, Goto, Yasushi, Sato, Jun, Morita, Ryo, Matsumoto, Yuji, Murakami, Shuji, Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2019

Number of metastatic organs negatively affects the treatment sequence in patients with EGFR‐TKI failure

por Mizuno, Takaaki, Horinouchi, Hidehito, Watanabe, Sho, Sato, Jun, Morita, Ryo, Murakami, Shuji, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Publicado 2020